­

Doporučené postupy psychiatrické péče
Psychiatrické společnosti ČLS JEP

Stáhnout kapitolu v PDF

Autoři: Michal Hrdlička, Iva Dudová

Garant: Michal Hrdlička

Oponent: Libuše Stárková

Farmakoterapie dětského autismu

Vysvětlivky:
ovál - nadpis 
kosočtverec - výběr z více variant
přerušovaná čára - diagram pokračuje na další straně 

 

Závěrečný komentář

Farmakoterapii lze u DA použít samostatně, nebo v kombinacemi s behaviorálními postupy uvedenými v další podkapitole. Rozhodnutí vždy záleží na individuálním posouzení daného případu.
Naše farmakoterapeutické algoritmy korespondují s oficiálními doporučeními americkými (AACAP official action, 2014) a britskými (NICE, 2013), jakkoli tato zahraniční doporučení nestrukturují posloupnost jednotlivých terapeutických kroků. Rovněž jsme využili doporučení renomované organizace Autism Speaks pro ADHD symptomy u autismu (Mahajan et al., 2012) a pro insomnii u autismu (Malow et al., 2012) a přihlédli jsme i k singapurským guidelines (Academy of Medicine Singapore- Ministry of Health Clinical Practice Guidelines Workgroup on Autism Spectrum Disorders, 2010). Většina dat pro sestavení výše uvedených doporučení byla získána pro diagnózu DA; pro další diagnózy z okruhu poruch autistického spektra je lze tedy použít jen s určitou opatrností.
Při definování symptomových okruhů pro intervenci jsme vyšli z prací renomovaných autorů (Rapin, 1997; McDougle et al., 2006), které byly již obecně akceptovány odbornou veřejností.

Reference

AACAP Official Action. Practice parameters for the assessment and treatment of children and adolescents with autism spectrum disorders. J Am Acad Child Adolesc Psychiatry 2014;53:237-257.
Academy of Medicine Singapore – Ministry of Health Clinical Practice Guidelines Workgroup on Autism Spectrum Disorders. Academy of Medicine Singapore – Ministry of Health Clinical Practice Guidelines: Autism spectrum disorders in pre-school children. Singapore Med J 2010;51:255-265.

Carrasco, M., Volkmar, F.R., Bloch, M.H. Pharmacologic treatment of repetitive behaviors in autism spectrum disorders: evidence of publication bias. Pediatrics 2012;129:e1301-e1310.

Cohen, S.A., Fitzgerald, B.J., Khan, S.R., et al. The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. J Clin Psychiatry 2004;65:110-113.

Hafterkamp, M., van de Loo-Neus, G., Minderaa, R.B., et al. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2012;51:733-741.

Hellings, J.A., Weckbaugh, M., Nickel, E.J., et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005;15:682-692.

Hollander, E., Chaplin, W., Soorya, L., et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 2010;35:990-998.

Hollander, E., Phillips, A., Chaplin, E., et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005;30:582-589.

Hollander, E., Wasserman, S., Swanson, E.N., et al. A double-blind placebo controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006;16:541-548.

King, B.H., Hollander, E., Sikich, L., et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior. Arch Gen Psychiatry 2009;66:583-590.

Mahajan, R., Bernal, M.P., Panzer, R., et al. Clinical practice pathways for evaluation and medication choice for attention-deficit/hyperactivity disorder symptoms in autism spectrum disorders. Pediatrics 2012;130:S125-S138.

Malow, B.A., Byars, K., Johnson, K., et al. A practice pathway for the identification, evaluation, and management of insomnia in children and adolescents with autism spectrum disorders. Pediatrics 2012;130:S106-S124

Marcus, R.N., Owen, R., Kamen, L., et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009;48:1110-1119.

McDougle, C.J., Kresch, L.E., Posey, D.J. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 2000;30:427-435.

McDougle, C.J., Kern, D.L., Posey, D.J. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002;41:921-927.

McDougle, C.J., Stigler, K.A., Erickson, C.A., et al. Pharmacology of autism. Clin Neurosci Res 2006;6:179-188.

National Institute for Health and Care Excellence (NICE). The NICE guideline on the management and support of children and young people on the autism spectrum. National Clinical Guideline Number 170. Leicester: British Psychological Society, 2013.

Owen, R., Sikich, L., Marcus, R.N., et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009;124:1533-1540.

Owley, T., Walton, L., Salt, J., et al. An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2005;44:343-348.

Rapin, I. Autism. N Engl J Med 1997;337:97-104.

Research Unit on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-321.

Research Unit on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005;62:1266-1274.

Rossignol, D.A., Frye, R.E. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011;53:783-792.

Shea, S., Turgay, A., Caroll, A., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autism and other pervasive developmental disorders. Pediatrics 2004;114:634-641.

Wasdell, M.B., Jan, J.E., Bomben, M.M., et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res 2008;44:57-64.

West, L., Brunssen, S.H., Waldrop, J. Review of the evidence for treatment of children with selective serotonin reuptake inhibitors. J Spec Pediatr Nurs 2009;14:183-191.

Williams, K., Brignell, K., Randall, M., et al. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews, 2013, Issue 8, Art. No.: CD004677.

Wright, B., Sims, D., Smart, S., et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behavioral management strategies: a randomised controlled crossover trial. J Autism Dev Disord 2011;41:175-184.

 

Datum zveřejnění: 10.6.2018

­